SolasCure has reported positive phase 2 data for Aurase Wound Gel in venous leg ulcers, showing faster debridement and wound healing versus standard of care

SolasCure has completed its second phase 2 clinical trial, Cleanvlu2, evaluating Aurase Wound Gel in patients with sloughy venous leg ulcers, reporting significantly faster debridement and wound area reduction compared with standard of care.

The Cambridge UK-based biotech said its investigational product combines a proprietary hydrogel with the active pharmaceutical ingredient tarumase. The study builds on earlier phase 2a data from Cleanvlu1, which established proof of concept and safety. Cleanvlu2 was designed to further assess efficacy and dose response in treatment-resistant venous leg ulcers.

According to the company, higher concentrations of tarumase were associated with greater clinical activity. Aurase Wound Gel achieved 65% debridement after 26 days compared with 9% in the control arm (p=0.005). Wound area reduction reached 58% versus 15% in the control group (p=0.022).

SolasCure said the treatment debrided sloughy wounds 22 times faster and achieved rates of healing seven times faster than standard of care, which included hydrogel, advanced moist wound dressings and compression bandaging systems.

The company said the data support a dual mechanism of action. In addition to continuous enzymatic removal of necrotic tissue, tarumase is designed to activate PAR2 receptors involved in tissue repair, triggering healing pathways from first application.

Aurase Wound Gel maintained what the company described as an excellent safety profile in the study, with no additional pain reported by patients. Improvements in quality of life measures across physical, psychological and daily living domains were also observed.

Chronic wounds represent a growing burden for healthcare systems globally, with venous leg ulcers among the most common and difficult-to-treat forms. Existing treatments typically focus on wound bed preparation and infection control rather than directly stimulating biological repair mechanisms.

Rob Kirsner, head of medical advisory board at SolasCure and chairman and Harvey Blank professor of dermatology at the University of Miami, said the phase 2 results “represent a highly encouraging advance in the treatment of chronic wounds. From a clinical perspective, the data demonstrate very effective debridement alongside meaningful activation of the biological processes leading to healing.”

The company said full clinical data from Cleanvlu2 will be submitted for peer-reviewed publication. It added that the results support advancement of Aurase Wound Gel into the next stage of development and ongoing discussions with investors and strategic partners.

While the announcement centres on clinical data, references to investor engagement suggest the update also serves to support future financing and partnership activity.